摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(苯氧基甲基)哌啶 | 405059-85-0

中文名称
3-(苯氧基甲基)哌啶
中文别名
——
英文名称
3-phenoxymethyl-piperidine
英文别名
3-(Phenoxymethyl)piperidine
3-(苯氧基甲基)哌啶化学式
CAS
405059-85-0
化学式
C12H17NO
mdl
MFCD08688464
分子量
191.273
InChiKey
VLXUUHNIFYPKBG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    295.9±13.0 °C(Predicted)
  • 密度:
    0.996±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    21.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-氯-3-(三氟甲基)[1,2,4]噻唑并[4,3-b]吡嗪3-(苯氧基甲基)哌啶 以Obtained in 60% yield by an analogous method to Example 515的产率得到6-[3-(phenoxymethyl)piperidin-1-yl]-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine
    参考文献:
    名称:
    BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155
    摘要:
    本发明涉及公式I的双环化合物,其中整数X1、X2、X3、环A、R4、R5和m如描述中所定义。本发明还涉及制备这种化合物的方法、包含它们的制药组合物以及它们在制造用于预防或治疗与雄激素受体相关疾病的药物中的应用。
    公开号:
    US20100016279A1
  • 作为产物:
    参考文献:
    名称:
    基于PSSRI的金黄色葡萄球菌多药外排泵抑制剂的合成和评估。
    摘要:
    苯哌啶选择性5-羟色胺再摄取抑制剂(PSSRIs)阻止了金黄色葡萄球菌的选定多药外排泵的功能。在这项研究中,制备了基于PSSRI的哌啶衍生物,评估了对两种具有多重耐药性(MDR)的外排泵系统的抑制作用,并测试了抗菌外排泵底物的抗菌活性。证明基于PSSRI的外排泵抑制剂(EPI)的4-苯基部分不是抑制NorA和MepA MDR外排泵的绝对结构要求。通过用芳基烯烃和芳基硫醚部分取代PSSRIs的3位上的芳氧基甲基取代基来维持或增强外排抑制的能力。新型3-芳基哌啶EPI可显着提高针对S菌株的底物抗生素活性。
    DOI:
    10.1016/j.bmcl.2008.01.014
点击查看最新优质反应信息

文献信息

  • Ligands for monoamine receptors and transporters, and methods of use thereof
    申请人:——
    公开号:US20030050309A1
    公开(公告)日:2003-03-13
    One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.
    本发明的一个方面涉及杂环化合物。本发明的第二个方面涉及将这些杂环化合物用作各种哺乳动物细胞受体的配体,包括多巴胺、5-羟色胺或去甲肾上腺素转运体。本发明的化合物将用于治疗许多困扰哺乳动物的疾病、症状和疾病,包括但不限于成瘾、焦虑、抑郁、性功能障碍、高血压、偏头痛、阿尔茨海默病、肥胖、呕吐、精神病、精神分裂症、帕金森病、炎症性疼痛、神经病性疼痛、Lesche-Nyhane病、威尔逊病和抽动症。本发明的另一个方面涉及合成这些杂环化合物的组合式库以及对这些库进行生物活性筛选,例如在基于多巴胺转运体的测定中。
  • Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter
    申请人:Aquila M. Brian
    公开号:US20050080078A1
    公开(公告)日:2005-04-14
    One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapuetically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a preferred embodiment, the method of the present invention treats cocaine addiction or methamphetamine addiction.
    本发明的一个方面涉及一种治疗哺乳动物药物成瘾或药物依赖的方法,包括向需要的哺乳动物施用治疗有效量的杂环化合物的步骤,例如,3-取代哌啶。在一个优选实施例中,本发明的方法治疗可卡因成瘾或甲基苯丙胺成瘾。
  • [EN] BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS<br/>[FR] DÉRIVÉS BICYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'AFFECTIONS ASSOCIÉES AU RÉCEPTEUR DES ANDROGÈNES
    申请人:ASTRAZENECA AB
    公开号:WO2009081197A1
    公开(公告)日:2009-07-02
    The invention concerns bicyclic compounds of Formula (I), wherein the integers X1, X2, X3, Ring A, R4, R5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.
    该发明涉及式(I)的双环化合物,其中整数X1、X2、X3、环A、R4、R5和m的定义如描述中所示。本发明还涉及制备这些化合物的方法、含有它们的药物组合物以及它们在制备用于预防或治疗雄激素受体相关疾病的药物中的应用。
  • Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound
    申请人:Ishii Takahiro
    公开号:US20100009971A1
    公开(公告)日:2010-01-14
    A novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound or its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound of the present disclosure is also useful in the treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.
    一种新型的吡啶基非芳香性含氮杂环-1-羧酸酯化合物或其药学上可接受的盐具有强效的FAAH抑制活性。此外,本公开的吡啶基非芳香性含氮杂环-1-羧酸酯化合物也可用于治疗尿频、尿失禁、过度活跃的膀胱和/或疼痛。
  • LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF
    申请人:Aquila Brian M.
    公开号:US20090258901A1
    公开(公告)日:2009-10-15
    One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.
    本发明的一个方面涉及杂环化合物。本发明的第二个方面涉及将杂环化合物用作各种哺乳动物细胞受体的配体,包括多巴胺、血清素或去甲肾上腺素转运体。本发明的化合物将用于治疗许多影响哺乳动物的疾病、状况和疾病,包括但不限于成瘾、焦虑、抑郁、性功能障碍、高血压、偏头痛、阿尔茨海默病、肥胖症、呕吐、精神病、精神分裂症、帕金森病、炎性疼痛、神经痛、Lesche-Nyhane病、威尔逊病和托瑞特综合症。本发明的另一个方面涉及合成杂环化合物的组合库,并对这些库进行生物活性筛选,例如基于多巴胺转运体的测定。
查看更多